Skip to main content
Premium Trial:

Request an Annual Quote

Charles Cantor, Jeffrey Skolnick, Andrzej Kolinski, Marcos Betancourt, Hassan Dayem


Strand Genomics of Bangalore, India, has appointed Charles Cantor, CSO at Sequenom, to its scientific advisory board. Cantor is a consultant to more than 16 biotech firms, has published more than 325 peer-reviewed articles, been granted 26 US patents, and recently completed a textbook on genomics called, “The Science and Technology of the Human Genome Project.”

Jeffrey Skolnick has been tapped to head the newly launched Buffalo Center of Excellence in Bioinformatics, based at the State University of New York at Buffalo. Skolnick is currently director of computational and structural genomics at the Danforth Plant Science Center in St. Louis. He’ll take the reins as executive director of the center on Sept. 30. He will also serve as a professor of structural biology at UB. Andrzej Kolinski and Marcos Betancourt will also leave the Danforth Center to join Skolnick in Buffalo.

Amgen of Thousand Oaks, Calif., has appointed Hassan Dayem as senior vice president and CIO. Dayem was previously VP of information services and CIO at Merck. He will oversee 500 IT professionals in the US and Europe at Amgen.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.